Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : Bio-Thera Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Bio-Thera, Dr. Reddy's Sign Agreement for Stelara, Simponi Biosimilars in SE Asia
Details : Under the agreement, Bio-Thera will maintain responsibility for the development of BAT2506 (Golimumab), while Reddy will have exclusive rights to commercialize the product in the Southeast Asia.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
March 27, 2025
Lead Product(s) : Golimumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : Bio-Thera Solutions
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy’s Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Details : DRL_RI is being developed as a biosimilar of Rituxan/MabThera (rituximab), a CD20 directed cytolytic antibody for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, ...
Product Name : Ituxredi
Product Type : Antibody
Upfront Cash : Inapplicable
December 07, 2023
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : Abatacept
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tocilizumab Biosimilar is a recombinant humanized monoclonal antibody targeting IL-6R, which specifically binds to sIL-6R and mIL-6R and inhibits signaling mediated by sIL-6R or mIL-6R. It is approved for the treatment of RA, sJIA, and CRS.
Product Name : DRL_TC
Product Type : Antibody
Upfront Cash : Inapplicable
May 06, 2023
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy’s Successfully Completes Phase 1 Study Of DRL_TC, a Proposed Biosimilar of Tocilizumab
Details : Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Product Name : DRL_TC
Product Type : Antibody
Upfront Cash : Inapplicable
December 19, 2022
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylprednisolone Sodium Succinate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Launches Generic Methylprednisolone Sodium Succinate for Injection in US
Details : Generic Methylprednisolone Sodium Succinate for injection, is the generic equivalent of Solumedrol, and has been approved by the U.S.FDA, indicated for various conditions including arthritis, blood disorders and severe allergic reactions.
Product Name : Methylprednisolone Sodium Succinate-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
June 04, 2022
Lead Product(s) : Methylprednisolone Sodium Succinate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Posaconazole
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Launch of posaconazole delayed-release tablets, 100 mg, therapeutic generic equivalent to NOXAFIL® (posaconazole) delayed-release tablets, 100 mg approved by U.S.FDA, indicated for prophylaxis of invasive aspergillus and candida infections in patients.
Product Name : Posaconazole-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2022
Lead Product(s) : Posaconazole
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 13, 2021
Lead Product(s) : Tocilizumab
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Study Phase : Approved FDF
Recipient : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Divestment
Details : The divested brand and its extensions represent two types of products, (a) Mometasone mono product and (b) combination of Mometasone with Azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.
Product Name : Momat Rino Advance
Product Type : Steroid
Upfront Cash : Undisclosed
November 28, 2020
Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Recipient : Glenmark Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 13, 2020
Lead Product(s) : Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : PPD
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
